Nightingale to start Eloisa pilot in public healthcare
Summary
- Nightingale Health announced a pilot project in South Savo, integrating its disease risk detection test into public primary healthcare, marking the first phase of a cooperation initiated in June 2025.
- The project offers free tests to residents aged 45, 50, and 55, identifying risks for five chronic diseases, with follow-up digital lifestyle coaching and testing funded by Sitra and Eloisa.
- The pilot is seen as a strategic opportunity for Nightingale to establish a presence in the public healthcare sector, although its immediate financial impact is expected to be limited.
- Long-term economic benefits are anticipated through extensive partnerships and increased volumes, with the pilot potentially leading to broader public sector contracts.
This content is generated by AI. You can give feedback on it in the Inderes forum.
Translation: Original published in Finnish on 09/15/2026 at 07:15 am EEST
Nightingale Health announced on Monday that residents of the South Savo Wellbeing Services County Eloisa, can register for the Wellbeing Gift (Hyvinvointilahja) research and development project. In the project, the company’s disease risk detection test is offered as part of primary healthcare. This is the first practical phase of the cooperation announced in June 2025. We view the news as a positive step forward, as it opens the door for the company into Finland's public primary healthcare. As this is a regional pilot project, we estimate that its immediate financial impact will remain limited for the time being. The news therefore does not cause immediate changes to our forecasts.
The pilot provides an important proving ground in the public sector
In the project, Eloisa offers its 45-, 50-, and 55-year-old residents Nightingale's test free of charge, which identifies the risk of developing five common chronic diseases. Individuals identified with an elevated risk are directed to digital lifestyle coaching, and a follow-up test conducted after six months shows how the disease risks have changed. The project is funded by Sitra and Eloisa, and scientific evaluation is led by the University of Eastern Finland. As we have previously estimated, the public healthcare sector opens up opportunities for Nightingale, but breaking into a slow-moving industry takes time. We believe that the project starting now is a good reference and a chance to prove itself for the company. This enables the company to demonstrate the impact of the operating model in public healthcare before a potential broader roll-out.
Economic scale is built over the long term
While the public sector breakthrough is strategically important, we estimate that the project's volumes and thus its direct revenue impact will remain moderate in the initial phase. The scaling of Nightingale's business model and the profitability turnaround necessitate that the company builds extensive partnerships with a long-term perspective and increases the volumes of existing agreements. We will follow the results of the Eloisa pilot with interest and its potential to act as a spearhead for broader public sector contracts in the future.